Boston Scientific(US:BSX)2026-02-04 14:02Financial Data and Key Metrics Changes - Fourth quarter consolidated revenue reached $5.286 billion, representing a 15.9% reported growth compared to Q4 2024, with operational revenue growth of 14.3% after excluding a $74 million foreign exchange tailwind [19] - Full year 2025 consolidated revenue was $20.074 billion, marking a 19.9% reported growth versus 2024, with operational revenue growth of 19.2% after excluding a $114 million foreign exchange tailwind [20] - Adjusted earnings per share for Q4 2025 was $0.80, a 15% increase from 2024, exceeding guidance [19] - Full year 2025 adjusted earnings per share was $3.06, growing 22% versus 2024, also exceeding guidance [20] - Adjusted gross margin for Q4 was 70.7%, with a full year adjusted gross margin of 70.6%, reflecting a 30 basis point expansion [21] Business Line Data and Key Metrics Changes - Urology sales grew 13% operationally in Q4 and 23% operationally for the full year, but performance was below expectations [5] - Endoscopy achieved organic growth of 8% in both Q4 and for the full year, driven by endoluminal surgery and imaging systems [5] - Neuromodulation grew 10% in Q4 and 8% for the full year, with the brain franchise showing low double-digit growth [6] - Cardiovascular segment delivered 16% growth operationally in Q4 and 22% operationally for the full year [7] - Watchman business grew 29% in Q4 and strong double-digit growth for the full year, driven by concomitant procedures [13] Market Data and Key Metrics Changes - U.S. market grew 17% in Q4 and 26% for the full year, with strong performance in EP, Watchman, and ICTX [3] - Asia Pacific region grew 15% operationally in Q4 and 14% for the full year, led by Japan and China [4] - Europe, Middle East, and Africa grew 5% in Q4 and 3% for the full year, with high single-digit growth excluding Acclarent discontinuation [3] Company Strategy and Development Direction - The company anticipates continued momentum in EP and Watchman, with expectations for higher growth in the second half of 2026 [4] - Strategic acquisitions, including Nalu Medical and Valencia Technologies, are aimed at enhancing the company's portfolio in neuromodulation and urology [24][25] - The company is focused on expanding its pain portfolio and enhancing operational efficiencies through new product launches and partnerships [7][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving organic growth of 10%-11% for 2026, with adjusted EPS growth of 12%-14% [27][28] - The company expects to maintain a strong market position despite competitive pressures, particularly in the EP segment [34][45] - Management highlighted the importance of upcoming clinical trial results, particularly for the Watchman product, which could significantly impact growth [81] Other Important Information - The company expects full-year free cash flow to be approximately $4.2 billion for 2026, with a target conversion rate of 70%-80% [24] - The adjusted tax rate for 2026 is forecasted to be around 12.5% [27] Q&A Session Summary Question: Concerns about U.S. EP and Watchman performance - Management noted that EP grew 35% in Q4, exceeding internal targets, and Watchman grew 29%, indicating strong market performance despite concerns [33][36] Question: Impact of recent trials on Watchman - Management confirmed no negative impact from recent trials and emphasized robust uptake of Watchman procedures [41] Question: Expectations for EP growth in 2026 - Management expects EP growth to exceed 15%, driven by new product approvals and market expansion [45] Question: Capacity issues in EP labs - Management acknowledged capacity constraints but emphasized ongoing efforts to build out ASCs and repurpose cath labs to alleviate wait times [72] Question: Confidence in long-term growth targets - Management remains confident in achieving 10%+ organic revenue growth through 2028, supported by strategic acquisitions and market leadership [86]